B. Riley initiated coverage of Corbus Pharmaceuticals with a Buy rating and $85 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals management to meet with Oppenheimer
- Corbus Pharmaceuticals price target raised to $82 from $77 at RBC Capital
- Corbus Pharmaceuticals’ Promising Cancer Drug Trial Results
- Corbus Pharmaceuticals price target raised to $80 from $60 at Oppenheimer
- SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024